Nandrolone phenylpropionate: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
[[Category:Phenylpropionate esters]] | [[Category:Phenylpropionate esters]] | ||
[[Category:Nandrolone esters]] | [[Category:Nandrolone esters]] | ||
== Nandrolone_phenylpropionate == | |||
<gallery> | |||
File:Nandrolone_phenylpropionate.svg|Chemical structure of Nandrolone phenylpropionate | |||
File:Nandrolone_phenylpropionate_molecule_ball.png|Ball-and-stick model of Nandrolone phenylpropionate molecule | |||
File:Nandrolone.svg|Chemical structure of Nandrolone | |||
</gallery> | |||
Latest revision as of 04:05, 18 February 2025
Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, is a synthetic anabolic-androgenic steroid (AAS) and the 1(2)-phenylpropionate ester of nandrolone. It was first introduced in 1957 and is marketed in many countries, including in the United States, Europe, and elsewhere worldwide.
Pharmacology[edit]
Nandrolone phenylpropionate is a prodrug of nandrolone. Like nandrolone, it has strong anabolic effects and weak androgenic effects, which give it a mild side effect profile and make it especially suitable for use in women and children. Nandrolone esters are used in the treatment of anemias, cachexia (wasting syndrome), osteoporosis, breast cancer, and for other indications.
Chemistry[edit]
Nandrolone phenylpropionate, or nandrolone 17β-phenylpropionate, is a synthetic estrane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β phenylpropionate ester of nandrolone (19-nortestosterone).
Society and culture[edit]
Nandrolone phenylpropionate was introduced for medical use in 1957. It was the first nandrolone ester to be introduced, followed by nandrolone decanoate in 1962, and has been one of the most widely used nandrolone esters.
See also[edit]
References[edit]
<references />


